• Explore /
  • Poster
  • / A phase I study of nanoliposomal irinotecan and 5-fluorouracil/folinic acid in combination with interleukin-1-alpha antagonist for advanced pancreatic cancer patients with cachexia (OnFX).

A phase I study of nanoliposomal irinotecan and 5-fluorouracil/folinic acid in combination with interleukin-1-alpha antagonist for advanced pancreatic cancer patients with cachexia (OnFX).

Abstract Video & Slides Poster

Authors

null

Andrew Eugene Hendifar

Samuel Oschin Cancer Center, Cedars-Sinai Medical Center, Los Angeles, CA

Andrew Eugene Hendifar , Sungjin Kim , Mourad Tighiouart , Emily Hautamaki , Haesoo Kim , Camille Ng , Jar-Yee Liu , Kevin S. Scher , Samuel J Klempner , Veronica Placencio-Hickok , Gillian Gresham , Jun Gong

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 ASCO Virtual Scientific Program

Session Type

Poster Session

Session Title

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Pancreatic Cancer

Clinical Trial Registration Number

NCT03207724

Citation

J Clin Oncol 38: 2020 (suppl; abstr 4634)

DOI

10.1200/JCO.2020.38.15_suppl.4634

Abstract #

4634

Poster Bd #

242

Abstract Disclosures

Similar Posters

First Author: Katelyn Mae Atkins

Poster

2023 ASCO Gastrointestinal Cancers Symposium

Efficacy of the third-line chemotherapy in patients with advanced pancreatic cancer.

Efficacy of the third-line chemotherapy in patients with advanced pancreatic cancer.

First Author: Bomi Kim

First Author: Do-Youn Oh

First Author: Manojkumar Bupathi